Scleroderma

Part I. Introduction

1. Historical Perspective of Scleroderma
Christopher P. Denton, Marco Matucci-Cerinic

Part II. Epidemiology, Genetics and Classification

2. Epidemiology, Environmental, and Infectious Risk Factors
Jammie K. Barnes, Luc Mouthon, Maureen D. Mayes

3. Genetic Factors
Shervin Assassi, Yannick Allanore

4. Disease Subsets in Clinical Practice
Robyn T. Domsic, Thomas A. Medsger

5. Evolving Concepts of Diagnosis and Classification
Sindhu R. Johnson, Lorinda Chung, Jaap Fransen, Frank H. J. Hoogen

6. Overlap Syndromes
Pia Moinzadeh, Christopher P. Denton

7. Juvenile Localized and Systemic Scleroderma
Lauren V. Graham, Amy S. Paller, Ivan Foeldvari

8. Morphea (Localized Scleroderma)
Noelle M. Teske, Heidi T. Jacobe

9. Scleroderma Mimics
Laura K. Hummers, Alan Tyndall

10. Systems Biology Approaches to Understanding the Pathogenesis of Systemic Sclerosis
J. Matthew Mahoney, Jaclyn N. Taroni, Michael L. Whitfield

Part III. The Biological Basis of Systemic Sclerosis

11. Introduction: The Etiopathogenesis of Systemic Sclerosis – An Integrated Overview
Carol Feghali-Bostwick, John Varga

12. Pathology of Systemic Sclerosis
Lisa M. Rooper, Frederic B. Askin

13. Inflammation and Immunity
Francesco Boin, Carlo Chizzolini

14. Autoantibodies as Markers and Possible Mediators of Scleroderma Pathogenesis
Kimberly Doering Maurer, Antony Rosen

15. The Clinical Aspects of Autoantibodies
Masataka Kuwana, Thomas A. Medsger

16. Mechanisms of Vascular Disease
Mirko Manetti, Bashar Kahaleh

17. Biomarkers in Systemic Sclerosis
Robert Lafyatis, Sergio A. Jimenez

18. Pathophysiology of Fibrosis in Systemic Sclerosis
Maria Trojanowska, John Varga

19. Overview of Animal Models
Yoshihide Asano, Jörg H. W. Distler

Part IV. Cardiovascular Manifestations and Management

20. Raynaud’s Phenomenon, Digital Ulcers and Nailfold Capillaroscopy
Ariane L. Herrick, Fredrick M. Wigley, Marco Matucci-Cerinic

21. Renal Crisis and Other Renal Manifestations of Scleroderma
Christopher P. Denton, Marie Hudson

22. Cardiac Involvement: Evaluation and Management
Sanjiv J. Shah, Ahmad Mahmood, J. Gerry Coghlan

Part V. Pulmonary Manifestations and Management

23. Overview of Lung Involvement: Diagnosis, Differential Diagnosis and Monitoring
Christopher P. Denton

24. Clinical Assessment of Lung Disease
Gregory J. Keir, Richard M. Silver, Athol U. Wells

25. Treatment of Interstitial Lung Disease
Kevin K. Brown, Vincent Cottin

26. Pathogenesis of Pulmonary Arterial Hypertension
Rubin M. Tuder, Markella Ponticos, Alan Holmes

27. Clinical Assessment of Pulmonary Hypertension
Harrison W. Farber, Marc Humbert

28. The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis
Stephen C. Mathai, N. Nazzareno Galié

Part VI. Gastrointestinal Manifestations and Management

29. Overview of Gastrointestinal Tract Involvement
Christopher P. Denton

30. Upper Gastrointestinal Tract: Manifestations of Systemic Sclerosis
John O. Clarke, John E. Pandolfino

31. Small and Large Intestinal Involvement and Nutritional Issues
Elizabeth Harrison, Charles Murray, Simon Lal

Part VII. Skin, Musculoskeletal and Other Complications

32. Calcinosis
Antonia Valenzuela, Lorinda Chung

33. Evaluation and Management of Skin Disease
Noëlle S. Sherber, Fredrick M. Wigley

34. Assessment and Management of Progressive Skin Involvement in Diffuse Scleroderma
Robert W. Simms

35. Skeletal Muscle Involvement
Andrew L. Mammen

36. Tendons, Joints, and Bone
Jérôme Avouac, Maya H. Buch, Yannick Allanore

37. Cancer in Systemic Sclerosis
Ami A. Shah, Masataka Kuwana

38. Overlooked Manifestations
Edward V. Lally, Ami A. Shah, Fredrick M. Wigley

39. Pregnancy
Eliza F. Chakravarty, Virginia Steen

Part VIII. Management and Outcome Assessment

40. Introduction to Section VIII: Management and Outcome Assessment
John Varga, Fredrick M. Wigley, Christopher P. Denton

41. Immunomodulatory, Immunoablative, and Biologic Therapies
Jacob M. Laar, Robert W. Simms

42. Investigative Approaches to Drug Therapy
Voon H. Ong, Christopher P. Denton

43. Drug Development and Regulatory Considerations for SSc Therapies
Timothy M. Wright

44. Physical and Occupational Therapy
Luc Mouthon, Janet L. Poole

45. Psychosocial Issues and Care for Patients with Systemic Sclerosis
Lisa R. Jewett, Linda Kwakkenbos, Vanessa C. Delisle, Brooke Levis, Brett D. Thombs

46. Clinical Trial Design in Systemic Sclerosis
Yossra A. Suliman, Harsh Agrawal, Daniel E. Furst

47. Measuring Disease Activity and Outcomes in Clinical Trials
Dinesh Khanna, Sindhu R. Johnson

48. Innovative Approaches to Clinical Trials in Systemic Sclerosis
Rucsandra Dobrota, Ulf Müller-Ladner, Oliver Distler

49. Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis
Monique Hinchcliff, Michael L. Whitfield

Part IX. Case Studies: Approach to Complex Clinical Problems

50. Managing the Ischemic Finger in Scleroderma
Fredrick M. Wigley

51. Scleroderma Renal Crisis
Edward P. Stern, Christopher P. Denton

52. Rapid Diffuse Skin Disease with Progressive Joint Contractures
Faye N. Hant, Richard M. Silver

53. Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy
Christopher J. Mullin, Stephen C. Mathai

54. Pseudo-obstruction with Malabsorption and Malnutrition
John O. Clarke

55. Progressive Interstitial Lung Disease Nonresponse to Cyclophosphamide
Katherine C. Silver, Kristin B. Highland, Richard M. Silver

56. Coping with the Disfigurement of Scleroderma: Facial, Skin, and Hand Changes
Shadi Gholizadeh, Rina S. Fox, Sarah D. Mills, Lisa R. Jewett, Brett D. Thombs, Vanessa L. Malcarne

57. Managing Complicated Digital Ulcers
Robert J. Spence

Nyckelord: Medicine & Public Health, Rheumatology, Pneumology/Respiratory System, Dermatology